Protagonist Therapeutics Receives Milestone Payment After FDA Approval of Icotyde
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy PTGX?
Source: stocktwits
Protagonist Therapeutics Inc. saw its stock rise by 5.54% as it crossed above the 5-day SMA, reflecting positive investor sentiment following significant news.
The FDA has approved Icotyde, a treatment for moderate-to-severe plaque psoriasis, which is expected to greatly enhance Protagonist's market position. This approval triggers a $50 million milestone payment to Protagonist, with eligibility for up to $580 million in future payments and tiered royalties of 6%-10% on sales, indicating a strong financial outlook for the company.
This milestone not only boosts Protagonist's immediate revenue but also positions the company favorably for future growth in treating other IL-23-driven diseases, enhancing its strategic importance in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTGX
Wall Street analysts forecast PTGX stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 105.400
Low
65.00
Averages
94.54
High
115.00
Current: 105.400
Low
65.00
Averages
94.54
High
115.00
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
Insider at Protagonist Therapeutics (PTGX.US) Plans to Sell $5.39 Million in Common Stock via Form 144
Stock Sale Announcement: Dinesh Patel plans to sell 54,700 shares of Protagonist Therapeutics (PTGX.US) on March 24, with a total market value of approximately $5.39 million.
Reduction in Holdings: Patel has reduced his shareholding in Protagonist Therapeutics by 48,273 shares since January 23, 2026, valued at around $4.06 million.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Icotyde Receives FDA Approval, Protagonist Hits Milestone
- FDA Approval Milestone: Icotyde has received FDA approval for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older, based on four late-stage studies involving 2,500 patients that met all primary endpoints and demonstrated a favorable safety profile, which is expected to significantly enhance Protagonist's market position.
- Milestone Payment Incentive: The FDA approval triggers a $50 million milestone payment to Protagonist, with eligibility for up to $580 million in additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales, greatly improving the company's financial outlook.
- Analyst Optimism: H.C. Wainwright analyst Douglas Tsao noted that the earlier-than-expected approval and
See More
Johnson & Johnson's Icotyde Receives FDA Approval
- FDA Approval: Johnson & Johnson's oral medication Icotyde has received FDA approval, becoming the first oral option for treating moderate to severe plaque psoriasis, expected to serve as the first-line systemic treatment between topical and injectable therapies.
- Significant Market Potential: J&J anticipates that Icotyde could exceed $5 billion in annual sales once approved for other autoimmune conditions, highlighting its substantial potential in the competitive psoriasis treatment market.
- Increased Patient Acceptance: The oral formulation of Icotyde is likely to appeal to approximately 75% of the 8 million U.S. psoriasis patients who do not transition from topical treatments to injections due to needle phobia, potentially enhancing patient adherence to treatment.
- Changing Competitive Landscape: Icotyde targets the same IL-23 receptor as J&J's Tremfya and AbbVie's Skyrizi, offering a relatively simple and safe treatment option that could alter the competitive dynamics in psoriasis treatment.
See More
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
See More
Insider at Protagonist Therapeutics (PTGX.US) Plans to Sell $5.39 Million in Common Stock via Form 144
Stock Sale Announcement: Dinesh Patel plans to sell 54,700 shares of Protagonist Therapeutics (PTGX.US) on March 24, with a total market value of approximately $5.39 million.
Reduction in Holdings: Patel has reduced his shareholding in Protagonist Therapeutics by 48,273 shares since January 23, 2026, valued at around $4.06 million.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
Icotyde Receives FDA Approval, Protagonist Hits Milestone
- FDA Approval Milestone: Icotyde has received FDA approval for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older, based on four late-stage studies involving 2,500 patients that met all primary endpoints and demonstrated a favorable safety profile, which is expected to significantly enhance Protagonist's market position.
- Milestone Payment Incentive: The FDA approval triggers a $50 million milestone payment to Protagonist, with eligibility for up to $580 million in additional regulatory and sales milestone payments, as well as tiered royalties ranging from 6% to 10% on global net sales, greatly improving the company's financial outlook.
- Analyst Optimism: H.C. Wainwright analyst Douglas Tsao noted that the earlier-than-expected approval and
See More
Johnson & Johnson's Icotyde Receives FDA Approval
- FDA Approval: Johnson & Johnson's oral medication Icotyde has received FDA approval, becoming the first oral option for treating moderate to severe plaque psoriasis, expected to serve as the first-line systemic treatment between topical and injectable therapies.
- Significant Market Potential: J&J anticipates that Icotyde could exceed $5 billion in annual sales once approved for other autoimmune conditions, highlighting its substantial potential in the competitive psoriasis treatment market.
- Increased Patient Acceptance: The oral formulation of Icotyde is likely to appeal to approximately 75% of the 8 million U.S. psoriasis patients who do not transition from topical treatments to injections due to needle phobia, potentially enhancing patient adherence to treatment.
- Changing Competitive Landscape: Icotyde targets the same IL-23 receptor as J&J's Tremfya and AbbVie's Skyrizi, offering a relatively simple and safe treatment option that could alter the competitive dynamics in psoriasis treatment.
See More
